StockNews.com downgraded shares of OraSure Technologies (NASDAQ:OSUR – Free Report) from a buy rating to a hold rating in a research note published on Saturday morning.
Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. decreased their price objective on shares of OraSure Technologies from $7.00 to $6.00 and set a neutral rating for the company in a report on Monday, May 13th. Evercore ISI increased their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an in-line rating in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $6.67.
Read Our Latest Report on OSUR
OraSure Technologies Price Performance
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its stake in OraSure Technologies by 727.5% in the second quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier’s stock valued at $8,610,000 after purchasing an additional 1,776,867 shares in the last quarter. Cannell Capital LLC raised its position in shares of OraSure Technologies by 25.8% during the 4th quarter. Cannell Capital LLC now owns 3,549,050 shares of the medical instruments supplier’s stock valued at $29,102,000 after buying an additional 728,459 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after buying an additional 605,324 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of OraSure Technologies by 30.1% during the 2nd quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock worth $7,710,000 after acquiring an additional 418,603 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in OraSure Technologies by 20.6% in the second quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock worth $9,749,000 after acquiring an additional 391,100 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Featured Articles
- Five stocks we like better than OraSure Technologies
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What is the Dow Jones Industrial Average (DJIA)?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.